Reports Q3 revenue $410,000 vs. $10.9M last year. “Following the close of the third quarter, we are very pleased to have signed a strategic ...

The sorghum salt tolerant gene SbTEF1 was identified by genome-wide association study (GWAS) and the PAV284 which located in ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.

LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

Enhancers play a crucial role in directing gene expression programs essential for cellular differentiation and development. Recent advancements in 3D genome ...

Discover how a maternal diet can influence the development of the genome, revealing the scientific basis for prenatal ...

Approach that uses cell’s own strategy of liquid-liquid phase separation protects synthetic modifications from being washed away by the tide of cell growth.

The wrongful death lawsuit ended Wednesday after Francis Stueber's family requested a full dismissal following a notice of settlement.

The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...